3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
8
Ovarian Neoplasms
6
Neoplasm Metastasis
4
Advanced Solid Tumors
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Fallopian Tube Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma, Ewing
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neuroendocrine Tumors
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Mesothelioma
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Interventions
Everolimus
10
lutetium Lu 177 dotatate
5
Magnetic Resonance Spectroscopy
5
pasireotide
4
Specimen Handling
3
Positron Emission Tomography Computed Tomography
3
Fluorodeoxyglucose F18
3
(177)Lu-DOTA-EB-TATE
3
olaparib
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
FAPI-46
2
veliparib
1
vandetanib
1
trifluridine tipiracil drug combination
1
toripalimab
1
tislelizumab
1
talazoparib
1
surufatinib
1
romidepsin
1
peposertib
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
fosbretabulin
1
fludarabine phosphate
1
exemestane
1
decitabine and cedazuridine drug combination
1
dactolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroendocrine Tumors
×
talazoparib
×
Clear all
NCT05053854
2025-02-20
PARLuNET
Peter MacCallum Cancer Centre, Australia
Phase 1
Recruiting
24 enrolled